Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies.

Trang M, Seroogy JD, Van Wart SA, Bhavnani SM, Kim A, Gibbons JA, Ambrose PG, Rubino CM.

Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.02329-18. doi: 10.1128/AAC.02329-18. [Epub ahead of print]

2.

APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an in vivo Model of Invasive Pulmonary Aspergillosis.

Zhao M, Lepak AJ, Marchillo K, Vanhecker J, Sanchez H, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.02372-18. doi: 10.1128/AAC.02372-18. [Epub ahead of print]

PMID:
30670426
3.

Time for Precision: A World Without Susceptibility Breakpoints.

Bader JC, Lakota EA, Andes DR, Rubino CM, Ambrose PG, Bhavnani SM.

Open Forum Infect Dis. 2018 Oct 31;5(12):ofy282. doi: 10.1093/ofid/ofy282. eCollection 2018 Dec.

4.

Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against S. aureus and S. pneumoniae.

Lepak AJ, Zhao M, Liu Q, Wang P, Wang Y, Bader JC, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Dec 17. pii: AAC.02404-18. doi: 10.1128/AAC.02404-18. [Epub ahead of print]

PMID:
30559140
5.

Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Mpagama SG, Bendet P, Srivastava S, Koeuth T, Lee PS, Bhavnani SM, Ambrose PG, Thwaites G, Heysell SK, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S293-S302. doi: 10.1093/cid/ciy611.

PMID:
30496461
6.

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Bendet P, Koeuth T, Bhavnani SM, Ambrose PG, Smythe W, McIlleron H, Thwaites G, Gumusboga M, Van Deun A, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S274-S283. doi: 10.1093/cid/ciy618.

PMID:
30496459
7.

Erratum for Drusano et al., "Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia".

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e00198-18. doi: 10.1128/AAC.00198-18. Print 2018 Apr. No abstract available.

8.

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.

Bader JC, Lakota EA, Flanagan S, Ong V, Sandison T, Rubino CM, Bhavnani SM, Ambrose PG.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02614-17. doi: 10.1128/AAC.02614-17. Print 2018 Jun.

9.

Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model.

Montero M, VanScoy BD, López-Causapé C, Conde H, Adams J, Segura C, Zamorano L, Oliver A, Horcajada JP, Ambrose PG.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00026-18. doi: 10.1128/AAC.00026-18. Print 2018 May.

10.

Correction to: PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.

Bulik CC, Bader JC, Zhang L, Van Wart SA, Rubino CM, Bhavnani SM, Sweeney KL, Ambrose PG.

J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):351. doi: 10.1007/s10928-018-9572-2.

PMID:
29446052
11.

Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal Activity.

Ambrose PG, VanScoy BD, Adams J, Fikes S, Bader JC, Bhavnani SM, Rubino CM.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02257-17. doi: 10.1128/AAC.02257-17. Print 2018 Apr.

12.

In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.

Zhao M, Lepak AJ, VanScoy B, Bader JC, Marchillo K, Vanhecker J, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02542-17. doi: 10.1128/AAC.02542-17. Print 2018 Apr.

13.

We can do better: a fresh look at echinocandin dosing.

Bader JC, Bhavnani SM, Andes DR, Ambrose PG.

J Antimicrob Chemother. 2018 Mar 1;73(3):831. doi: 10.1093/jac/dky013. No abstract available.

PMID:
29340605
14.

We can do better: a fresh look at echinocandin dosing.

Bader JC, Bhavnani SM, Andes DR, Ambrose PG.

J Antimicrob Chemother. 2018 Jan 1;73(suppl_1):i44-i50. doi: 10.1093/jac/dkx448. Review.

PMID:
29304211
15.

Reply to Paul and Leibovici.

Boucher HW, Ambrose PG, Chambers HF, Ebright RH, Jezek A, Murray BE, Ostrowsky B, Rex JH.

J Infect Dis. 2018 Jan 17;217(3):509-510. doi: 10.1093/infdis/jix537. No abstract available.

PMID:
29240925
16.

Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design.

Lepak AJ, Zhao M, VanScoy B, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02154-17. doi: 10.1128/AAC.02154-17. Print 2018 Feb.

17.

β-Lactamase inhibitors: what you really need to know.

Ambrose PG, Lomovskaya O, Griffith DC, Dudley MN, VanScoy B.

Curr Opin Pharmacol. 2017 Oct;36:86-93. doi: 10.1016/j.coph.2017.09.001. Epub 2017 Oct 27. Review.

PMID:
29096172
18.

Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia.

Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, Chastre J, Combes A, Walsh TJ, Dorizas K, Alnuaimat H, Morgan BE, Rello J, Mazo CA, Jones RN, Flamm RK, Woosley L, Ambrose PG, Bhavnani S, Rubino CM, Bulik CC, Louie A, Vicchiarelli M, Berman C.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01323-17. doi: 10.1128/AAC.01323-17. Print 2018 Jan. Erratum in: Antimicrob Agents Chemother. 2018 Mar 27;62(4):.

19.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an In Vitro Infection Model.

VanScoy BD, Tenero D, Turner S, Livermore DM, McCauley J, Conde H, Bhavnani SM, Rubino CM, Ambrose PG.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01052-17. doi: 10.1128/AAC.01052-17. Print 2017 Dec.

20.

Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.

Ambrose PG, VanScoy BD, Trang M, McCauley-Miller J, Conde H, Bhavnani SM, Alexander DC, Friedrich LV.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00630-17. doi: 10.1128/AAC.00630-17. Print 2017 Dec.

21.

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.

Lakota EA, Bader JC, Ong V, Bartizal K, Miesel L, Andes DR, Bhavnani SM, Rubino CM, Ambrose PG, Lepak AJ.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00758-17. doi: 10.1128/AAC.00758-17. Print 2017 Nov.

22.

Antibacterial drug development program successes and failures: a pharmacometric explanation.

Ambrose PG.

Curr Opin Pharmacol. 2017 Oct;36:1-7. doi: 10.1016/j.coph.2017.06.002. Epub 2017 Jul 5.

PMID:
28688237
23.

White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs.

Boucher HW, Ambrose PG, Chambers HF, Ebright RH, Jezek A, Murray BE, Newland JG, Ostrowsky B, Rex JH; Infectious Diseases Society of America.

J Infect Dis. 2017 Jul 15;216(2):228-236. doi: 10.1093/infdis/jix211. Review.

24.

In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Lepak AJ, Zhao M, VanScoy B, Taylor DS, Ellis-Grosse E, Ambrose PG, Andes DR.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00476-17. doi: 10.1128/AAC.00476-17. Print 2017 Jun.

25.

PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.

Bulik CC, Bader JC, Zhang L, Van Wart SA, Rubino CM, Bhavnani SM, Sweeney KL, Ambrose PG.

J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):161-177. doi: 10.1007/s10928-017-9518-0. Epub 2017 Mar 28. Erratum in: J Pharmacokinet Pharmacodyn. 2018 Feb 14;:.

PMID:
28353185
26.

Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.

Bulik CC, Okusanya ÓO, Lakota EA, Forrest A, Bhavnani SM, Hoover JL, Andes DR, Ambrose PG.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e00115-16. doi: 10.1128/AAC.00115-16. Print 2017 Feb.

27.

Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against Itself.

Ambrose PG, VanScoy B, Conde H, McCauley J, Rubino CM, Bhavnani SM.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01605-16. doi: 10.1128/AAC.01605-16. Print 2017 Jan.

28.

Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model.

VanScoy B, McCauley J, Bhavnani SM, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5141-5. doi: 10.1128/AAC.00355-16. Print 2016 Sep.

29.

Pharmacokinetics-Pharmacodynamics of a Novel β-Lactamase Inhibitor, CB-618, in Combination with Meropenem in an In Vitro Infection Model.

VanScoy BD, Trang M, McCauley J, Conde H, Bhavnani SM, Friedrich LV, Alexander DC, Ambrose PG.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3891-6. doi: 10.1128/AAC.02943-15. Print 2016 Jul.

30.

Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.

Nicasio AM, VanScoy BD, Mendes RE, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2075-80. doi: 10.1128/AAC.02747-15. Print 2016 Apr.

31.

Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.

Bhavnani SM, Ambrose PG, Hammel JP, Rubino CM, Drusano GL.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1600-7. doi: 10.1128/AAC.02967-15.

32.

Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.

VanScoy BD, McCauley J, Ellis-Grosse EJ, Okusanya OO, Bhavnani SM, Forrest A, Ambrose PG.

Antimicrob Agents Chemother. 2015 Dec;59(12):7170-7. doi: 10.1128/AAC.04955-14. Epub 2015 Jun 22.

33.

In memoriam: William A. Craig.

Theuretzbacher U, Ambrose PG, MacGowan AP, Andes DR, Sörgel F, Derendorf H, Mouton JW, Drusano GL, Tulkens PM, Dudley MN, Cars O, Nation RL.

Antimicrob Agents Chemother. 2015;59(6):2971. doi: 10.1128/AAC.00849-15. Epub 2015 Apr 20. No abstract available.

34.

Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.

Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG.

Antimicrob Agents Chemother. 2015;59(6):3365-72. doi: 10.1128/AAC.00176-15. Epub 2015 Mar 30.

35.

Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections.

Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Drusano GL, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.

Antimicrob Agents Chemother. 2015 Jan;59(1):372-80. doi: 10.1128/AAC.02531-14. Epub 2014 Nov 3.

36.

Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections.

Rubino CM, Xue B, Bhavnani SM, Prince WT, Ivezic-Schoenfeld Z, Wicha WW, Ambrose PG.

Antimicrob Agents Chemother. 2015 Jan;59(1):282-8. doi: 10.1128/AAC.02033-13. Epub 2014 Oct 27.

37.

Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.

VanScoy BD, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2014 Oct;58(10):6024-31. doi: 10.1128/AAC.02310-13. Epub 2014 Jul 28.

38.

Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.

Okusanya OO, Bhavnani SM, Hammel JP, Forrest A, Bulik CC, Ambrose PG, Gupta R.

Antimicrob Agents Chemother. 2014 Sep;58(9):5005-15. doi: 10.1128/AAC.02421-13. Epub 2014 Mar 31.

39.

Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.

Van Wart SA, Ambrose PG, Rubino CM, Khariton T, Riccobene TA, Friedland HD, Critchley IA, Bhavnani SM.

Antimicrob Agents Chemother. 2014;58(2):885-91. doi: 10.1128/AAC.01680-13. Epub 2013 Nov 25.

40.

Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.

Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Khariton T, Friedland HD, Riccobene TA, Ambrose PG.

Antimicrob Agents Chemother. 2013 Dec;57(12):6348-50. doi: 10.1128/AAC.01748-13. Epub 2013 Sep 16.

41.

Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.

Vanscoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2013 Dec;57(12):5924-30. doi: 10.1128/AAC.00656-13. Epub 2013 Sep 16.

42.

Commentary: revised susceptibility breakpoints: fear, loathing and good science.

Dudley MN, Ambrose PG, Jones RN.

Pediatr Infect Dis J. 2013 Sep;32(9):970-1. doi: 10.1097/INF.0b013e3182a1b8cd. No abstract available.

PMID:
24008738
43.

Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia.

Van Wart SA, Forrest A, Khariton T, Rubino CM, Bhavnani SM, Reynolds DK, Riccobene T, Ambrose PG.

J Clin Pharmacol. 2013 Nov;53(11):1155-67. doi: 10.1002/jcph.153. Epub 2013 Aug 14.

PMID:
23907740
44.

Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.

Vanscoy B, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Forrest A, Jones RN, Okusanya OO, Friedrich LV, Steenbergen J, Ambrose PG.

Antimicrob Agents Chemother. 2013 Sep;57(9):4134-8. doi: 10.1128/AAC.00461-13. Epub 2013 Jun 17.

45.

Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.

Rayner CR, Bulik CC, Kamal MA, Reynolds DK, Toovey S, Hammel JP, Smith PF, Bhavnani SM, Van Wart SA, Ambrose PG, Forrest A.

Antimicrob Agents Chemother. 2013 Aug;57(8):3478-87. doi: 10.1128/AAC.02440-12. Epub 2013 May 13.

46.

Population pharmacokinetics of oseltamivir: pediatrics through geriatrics.

Kamal MA, Van Wart SA, Rayner CR, Subramoney V, Reynolds DK, Bulik CC, Smith PF, Bhavnani SM, Ambrose PG, Forrest A.

Antimicrob Agents Chemother. 2013 Aug;57(8):3470-7. doi: 10.1128/AAC.02438-12. Epub 2013 May 13.

47.

Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.

VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG.

Antimicrob Agents Chemother. 2013 Jun;57(6):2809-14. doi: 10.1128/AAC.02513-12. Epub 2013 Apr 29.

48.

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN; Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute.

Clin Infect Dis. 2013 May;56(9):1301-9. doi: 10.1093/cid/cit017. Epub 2013 Jan 18. Review.

PMID:
23334813
49.

Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance.

Bulitta JB, Okusanya OO, Forrest A, Bhavnani SM, Clark K, Still JG, Fernandes P, Ambrose PG.

Antimicrob Agents Chemother. 2013 Jan;57(1):498-507. doi: 10.1128/AAC.01354-12. Epub 2012 Nov 12.

50.

New EMA guideline for antimicrobial development.

Ambrose PG, Bhavnani SM, Dudley MN, Ellis-Grosse E, Rubino CM, Drusano GL.

Lancet Infect Dis. 2012 Apr;12(4):265-6. doi: 10.1016/S1473-3099(12)70046-4. No abstract available.

PMID:
22459079

Supplemental Content

Loading ...
Support Center